These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 16380670)

  • 1. Effect of rosiglitazone on early-morning plasma cortisol levels.
    Catrina SB; Virtanen K; Hällsten K; Lönnqvist F; Nuutila P; Brismar K
    Neuro Endocrinol Lett; 2005 Dec; 26(6):763-4; author reply 765. PubMed ID: 16380670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.
    Suri D; Weiss RE
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1340-6. PubMed ID: 15585550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease.
    Cannavò S; Ambrosi B; Chiodini I; Vigo T; Russo A; Milici C; Barbetta L; Dall'Asta C; Adda G; Arosio M
    J Endocrinol Invest; 2004 May; 27(5):RC8-11. PubMed ID: 15279069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
    Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
    Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease.
    Ambrosi B; Dall'Asta C; Cannavo S; Libe R; Vigo T; Epaminonda P; Chiodini I; Ferrero S; Trimarchi F; Arosio M; Beck-Peccoz P
    Eur J Endocrinol; 2004 Aug; 151(2):173-8. PubMed ID: 15296471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
    Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
    J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PPAR-γ reduces HPA axis activity in diabetic rats by up-regulating PI3K expression.
    Torres RC; Magalhães NS; E Silva PM; Martins MA; Carvalho VF
    Exp Mol Pathol; 2016 Oct; 101(2):290-301. PubMed ID: 27725163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment.
    Kok P; Kok SW; Buijs MM; Westenberg JJ; Roelfsema F; Frölich M; Stokkel MP; Meinders AE; Pijl H
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E848-56. PubMed ID: 15280154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
    Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
    Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
    Gruszka A; Kunert-Radek J; Pawlikowski M
    Neuro Endocrinol Lett; 2005 Feb; 26(1):51-4. PubMed ID: 15726020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients.
    Kling MA; Demitrack MA; Whitfield HJ; Kalogeras KT; Listwak SJ; DeBellis MD; Chrousos GP; Gold PW; Brandt HA
    Neuroendocrinology; 1993 Jun; 57(6):1082-91. PubMed ID: 8232766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients.
    van Wijk J; Coll B; Cabezas MC; Koning E; Camps J; Mackness B; Joven J
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1134-7. PubMed ID: 17184491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.
    Munir A; Song F; Ince P; Walters SJ; Ross R; Newell-Price J
    J Clin Endocrinol Metab; 2007 May; 92(5):1758-63. PubMed ID: 17311852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome.
    Mullan KR; Leslie H; McCance DR; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 2006 May; 64(5):519-22. PubMed ID: 16649970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.
    Pecori Giraldi F; Scaroni C; Arvat E; Martin M; Giordano R; Albiger N; Leao AA; Picu A; Mantero F; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):219-24. PubMed ID: 16430724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
    Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK
    Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
    Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus.
    de Boer RA; Martens FM; Kuipers I; Boomsma F; Visseren FL
    J Hum Hypertens; 2010 Jan; 24(1):74-6. PubMed ID: 19847195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.